Rectiv Approval History

  • FDA approved: Yes (First approved June 21st, 2011)
  • Brand name: Rectiv
  • Generic name: nitroglycerin
  • Company: ProStrakan Group plc
  • Treatment for: Anal Fissure and Fistula

Rectiv (nitroglycerin) is a topical ointment for the treatment of moderate to severe pain associated with chronic anal fissures.

FDA Approval History for Rectiv

DateArticle
Jun 22, 2011Approval ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures
Jul 10, 2006FDA Issues Approvable Letter to Cellegy Pharmaceuticals for Cellegesic
Jan  9, 2006Cellegy Reports Review by Advisory Committee April 2006
Jun 30, 2005Cellegy Reports Status of Response Date for FDA Review
May  5, 2005Cellegy Reports New FDA Target Response Date of June 15
Apr 18, 2005Cellegy Responds to FDA Inquiries Concerning Cellegesic
Dec 23, 2004FDA Issues Not Approvable Letter for Cellegesic
Oct 14, 2004Cellegesic Granted Priority Review by FDA
Sep  1, 2004NDA for Cellegesic is Accepted for Review by FDA
Jun 30, 2004Cellegy Submits NDA for Cellegesic to Treat Chronic Anal Fissure Pain

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)